{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:44:13Z","timestamp":1761896653532,"version":"3.40.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","publichealthjrnl.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Public Health"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.puhe.2017.08.011","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T14:34:23Z","timestamp":1506177263000},"page":"64-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Trends in the use and cost of human and analogue insulins in a Colombian population, 2011\u20132015"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5697-0493","authenticated-orcid":false,"given":"D.R.","family":"Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Portilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Machado-Duque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"J.E.","family":"Machado-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.puhe.2017.08.011_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.puhe.2017.08.011_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1590\/S1020-49892010001200008","article-title":"Treatment of type 2 diabetes in\u00a0Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association","volume":"28","author":"Guzm\u00e1n","year":"2010","journal-title":"Rev Panam Salud Publica"},{"issue":"1","key":"10.1016\/j.puhe.2017.08.011_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.mcna.2014.08.016","article-title":"Insulin therapy in type 1 diabetes","volume":"99","author":"Stephens","year":"2015","journal-title":"Med Clin N Am"},{"issue":"4","key":"10.1016\/j.puhe.2017.08.011_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1503\/cmaj.081180","article-title":"Cost-effectiveness of insulin analogues for diabetes mellitus","volume":"180","author":"Cameron","year":"2009","journal-title":"Cmaj"},{"issue":"2","key":"10.1016\/j.puhe.2017.08.011_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005613.pub3","article-title":"Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus","author":"Horvath","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.puhe.2017.08.011_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012161","article-title":"Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus","author":"Fullerton","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.puhe.2017.08.011_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40258-013-0073-6","article-title":"Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review","volume":"12","author":"Caires de Souza","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.puhe.2017.08.011_bib8","doi-asserted-by":"crossref","first-page":"c7139","DOI":"10.1136\/bmj.c7139","article-title":"How small changes led to big profits for insulin manufacturers","volume":"341","author":"Cohen","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.puhe.2017.08.011_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12954","article-title":"Effectiveness and clinical inertia in patients with antidiabetic therapy","volume":"71","author":"Machado-Duque","year":"2017","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.puhe.2017.08.011_bib10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.socscimed.2008.12.049","article-title":"Bureaucratic Itineraries in Colombia. A theoretical and methodological tool to assess managed-care health care systems","volume":"68","author":"Abadia","year":"2009","journal-title":"Soc Sci Med"},{"year":"2011","author":"Ministerio","series-title":"Ministerio de Salud y Protecci\u00f3n Social","key":"10.1016\/j.puhe.2017.08.011_bib11"},{"issue":"5","key":"10.1016\/j.puhe.2017.08.011_bib12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/diacare.23.5.639","article-title":"Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in type 1 diabetes","volume":"23","author":"Ratner","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.puhe.2017.08.011_bib13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.diabres.2015.01.018","article-title":"Time to and factors associated with insulin initiation in patients with type 2 diabetes mellitus","volume":"107","author":"Machado-Alba","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"36","key":"10.1016\/j.puhe.2017.08.011_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14360","article-title":"Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation","volume":"14","author":"Waugh","year":"2010","journal-title":"Health Technol Assess"},{"issue":"4","key":"10.1016\/j.puhe.2017.08.011_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1503\/cmaj.081041","article-title":"Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis","volume":"180","author":"Singh","year":"2009","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.puhe.2017.08.011_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.diabres.2014.12.007","article-title":"Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study","volume":"108","author":"Rafaniello","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.puhe.2017.08.011_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11845-013-1011-1","article-title":"Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003-2012","volume":"183","author":"Zaharan","year":"2014","journal-title":"Ir J Med Sci"},{"issue":"7309","key":"10.1016\/j.puhe.2017.08.011_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/bmj.323.7309.378","article-title":"Prescribing new drugs: qualitative study of influences on consultants and general practitioners","volume":"323","author":"Jones","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.puhe.2017.08.011_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.vhri.2015.02.002","article-title":"Results of the inclusion of new medications in the obligatory health system plan in Colombia, 2012\u20132013","volume":"8","author":"Machado-Alba","year":"2015","journal-title":"Value Health Regional Issues"},{"issue":"2","key":"10.1016\/j.puhe.2017.08.011_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40273-016-0456-2","article-title":"Systematic review of the cost effectiveness of insulin analogues in type 1 and type 2 diabetes mellitus","volume":"35","author":"Shafie","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.puhe.2017.08.011_bib21","first-page":"e235","article-title":"Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus","volume":"21","author":"Prentice","year":"2015","journal-title":"Am J Manag Care"},{"issue":"8","key":"10.1016\/j.puhe.2017.08.011_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1463-1326.2011.01394.x","article-title":"Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes","volume":"13","author":"Rhoads","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.puhe.2017.08.011_bib23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3111\/13696998.2013.768999","article-title":"Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden","volume":"16","author":"Ridderstrale","year":"2013","journal-title":"J Med Econ"},{"year":"2013","author":"Comisi\u00f3n","series-title":"Comisi\u00f3n Nacional de Precios de Medicamentos y Dispositivos M\u00e9dicos","key":"10.1016\/j.puhe.2017.08.011_bib24"}],"container-title":["Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350617302937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350617302937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T05:24:39Z","timestamp":1535347479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033350617302937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":24,"alternative-id":["S0033350617302937"],"URL":"https:\/\/doi.org\/10.1016\/j.puhe.2017.08.011","relation":{},"ISSN":["0033-3506"],"issn-type":[{"type":"print","value":"0033-3506"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in the use and cost of human and analogue insulins in a Colombian population, 2011\u20132015","name":"articletitle","label":"Article Title"},{"value":"Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.puhe.2017.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}